Pharmaceutical company defense lawyers have scored several recent victories in securities class actions in Boston federal court, but a pending U.S. Supreme Court case about the criteria for complaints in securities cases could expose the industry to a new round of securities litigation.
Several dozen cases against about one dozen pharmaceutical companies have clogged Boston’s federal docket during the past four years, but recent defense victories have thinned the ranks of pending consolidated class actions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
